Literature DB >> 18211251

17-Hydroxyprogesterone in premature infants as a marker of intrauterine stress.

Jörg Ersch1, Ernst Beinder, Thomas Stallmach, Hans Ulrich Bucher, Toni Torresani.   

Abstract

AIMS: Amniotic infection (AI) and preeclampsia (PE), which are commonly the reason for prematurity, inflict stress of different duration on immature fetuses. Whether chronic stress, as reflected by intrauterine growth retardation, influences the level of 17-OH progesterone (17-OHP), was not previously examined.
METHODS: We analyzed 17-OHP and TSH levels during neonatal screenings in the first hours of life of 90 premature infants born between 25 and 33 weeks of gestation in infants with AI (n=37) or with PE (n=53). Control of acute stress parameters was derived from umbilical arterial cord blood pH and base excess (BE).
RESULTS: Mean 17-OHP levels of infants born to mothers with PE were 85.7 nmol/L compared to 54.6 nmol/L (P<0.001) in AI infants. 17-OHP was even higher when intrauterine growth restriction was present (99.8 nmol/L). Antenatal steroids and mode of delivery did not significantly affect 17-OHP levels.
CONCLUSIONS: Stress of relatively long duration, as in cases of PE, leads to a significant increase of 17-OHP level in preterm infants. The postnatal 17-OHP level may be considered as a measure for severity of intrauterine stress and might be used as an individualized indicator for earlier intensive care.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18211251     DOI: 10.1515/JPM.2008.013

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  9 in total

1.  Precursor-to-product ratios reflect biochemical phenotype in congenital adrenal hyperplasia.

Authors:  Rebecca A Hicks; Jennifer K Yee; Catherine S Mao; Steve Graham; Martin Kharrazi; Fred Lorey; W P Lee
Journal:  Metabolomics       Date:  2014-02-01       Impact factor: 4.290

2.  Analysis of a pitfall in congenital adrenal hyperplasia newborn screening: evidence of maternal use of corticoids detected on dried blood spot.

Authors:  Muriel Houang; Thao Nguyen-Khoa; Thibaut Eguether; Bettina Ribault; Séverine Brabant; Michel Polak; Irène Netchine; Antonin Lamazière
Journal:  Endocr Connect       Date:  2022-06-15       Impact factor: 3.221

3.  Perinatal factors associated with neonatal thyroid-stimulating hormone in normal newborns.

Authors:  Seong Yong Lee
Journal:  Ann Pediatr Endocrinol Metab       Date:  2016-12-31

4.  Utility of a precursor-to-product ratio in the evaluation of presumptive positives in newborn screening of congenital adrenal hyperplasia.

Authors:  P Y Tieh; J K Yee; R A Hicks; C S Mao; W-Np Lee
Journal:  J Perinatol       Date:  2016-12-08       Impact factor: 2.521

5.  Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand.

Authors:  Mark R de Hora; Natasha L Heather; Tejal Patel; Lauren G Bresnahan; Dianne Webster; Paul L Hofman
Journal:  Int J Neonatal Screen       Date:  2020-01-28

6.  Morphologic Markers of Acute and Chronic Stress in Child Abuse.

Authors:  Mark A Flomenbaum; Ryan C Warner
Journal:  Am J Clin Pathol       Date:  2022-06-07       Impact factor: 5.400

7.  Maternal progesterone level in fetal growth restriction and its relationship with Doppler velocimetry indices.

Authors:  S Borna; M Bandarian; A Abdollahi; F Bandarian; M Malek
Journal:  Iran J Radiol       Date:  2011-03-30       Impact factor: 0.212

8.  Differential effects of hydrocortisone, prednisone, and dexamethasone on hormonal and pharmacokinetic profiles: a pilot study in children with congenital adrenal hyperplasia.

Authors:  Todd D Nebesio; Jamie L Renbarger; Zeina M Nabhan; Sydney E Ross; James E Slaven; Lang Li; Emily C Walvoord; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2016-09-26

Review 9.  Newborn Screening for Congenital Adrenal Hyperplasia: Review of Factors Affecting Screening Accuracy.

Authors:  Patrice K Held; Ian M Bird; Natasha L Heather
Journal:  Int J Neonatal Screen       Date:  2020-08-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.